Fundraising Fox
/Companies
Sign in

Jupiter Orphan Therapeutics

NASDAQ: JUNS

Jupiter, US · Founded 2016 · Delaware corporation · 1 known investors

Find your way into Jupiter Orphan Therapeutics

Sign up to see every warm intro you have to Jupiter Orphan Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Jupiter Orphan Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Jupiter Neurosciences develops JOTROL, an enhanced resveratrol formulation designed to address neuroinflammatory and central nervous system disorders, with a Phase IIa trial underway in Parkinson's Disease, while also selling wellness supplements under the Nugevia brand through direct-to-consumer channels.

Healthtech

Founders & leadership

JU
Jacob UittenbogaardChief Financial Officer
MH
Marshall HaywardChief Scientific Officer
CR
Christer RosénChief Executive Officer and President
SE
Saleem ElmasriChief Financial Officer
AR
Alexander RosénChief Administrative Officer
AD
Alison D. SilvaPresident and Chief Operating Officer, and Director
CW
Claes WahlestedtConsulting Chief Medical Officer

Board

NH
Nicholas HemmerlyBoard director
HW
Holger WeissBoard director
AC
Andrew CutlerBoard director
TP
Tomas PhilipsonBoard director

Investors · 1

Reported raises · per SEC filings

Form D private placements

$2.1M disclosed across 4 rounds · 2016–2026

▶$774.8KraisedSep 2026 · 1 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Christer RosenExecutive Officer, Director
  • Alison SilvaExecutive Officer, Director
  • Saleem ElmasriExecutive Officer
  • Marshall HaywardExecutive Officer, Director
  • Alexander RosenExecutive Officer
  • Nicholas HemmerlyDirector
  • Holger WeissDirector
  • Andrew CutlerDirector
  • Tomas PhilipsonDirector
Offering amount
$774.8K
Amount sold
$774.8K
First sale
Aug 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$100KraisedDec 2017 · 1 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Marshall HaywardExecutive Officer, Director
  • Christer RosenExecutive Officer, Director
  • Natalie McNameeDirector
  • Claes WahlestedtExecutive Officer, Director
  • Jacob UittenbogaardExecutive Officer, Director
Offering amount
$100K
Amount sold
$100K
First sale
Nov 2017
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1MraisedDec 2016 · 1 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Natalie McNameeDirector
  • Claes WahlestedtExecutive Officer, Director
  • Jacob UittenbogaardExecutive Officer, Director
  • Christer RosenExecutive Officer, Director
  • Marshall HaywardExecutive Officer, Director
Offering amount
$1M
Amount sold
$1M
First sale
Dec 2016
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$250KraisedJul 2016 · 1 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Jacob UittenbogaardExecutive Officer, Director
  • Marshall HaywardExecutive Officer, Director
  • Claes WahlestedtExecutive Officer, Director
  • Christer RosenExecutive Officer, Director
Offering amount
$4.5M
Amount sold
$250K
First sale
Jun 2016
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2020$2M

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Investing in Alzheimer’s Treatment: Join Jupiter Orphan Therapeutics for Fireside Chat March 30finance.yahoo.com · Mar 2021Jupiter Orphan Therapeutics - Tech Company Profile - Gaebler.com Venture Capital Databasegaebler.com

Frequently asked questions

What does Jupiter Orphan Therapeutics do?
Jupiter Neurosciences develops JOTROL, an enhanced resveratrol formulation designed to address neuroinflammatory and central nervous system disorders, with a Phase IIa trial underway in Parkinson's Disease, while also selling wellness supplements under the Nugevia brand through direct-to-consumer channels.
Who are Jupiter Orphan Therapeutics's investors?
Jupiter Orphan Therapeutics's investors include Tarnagulla Ventures.
How much funding has Jupiter Orphan Therapeutics raised?
Jupiter Orphan Therapeutics has disclosed $2.1M raised across 4 rounds.
Where is Jupiter Orphan Therapeutics headquartered?
Jupiter Orphan Therapeutics is headquartered in Jupiter, US.